Total Payments
$155,982
2024 Payments
$88,629
Companies
19
Transactions
212
Medicare Patients
2,897
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$115,464 (74.0%)
Travel$19,006 (12.2%)
Consulting$15,127 (9.7%)
Food & Beverage$6,215 (4.0%)
Education$169.86 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,638 | 46 | 59.4% |
| Travel and Lodging | $19,006 | 59 | 12.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $16,724 | 10 | 10.7% |
| Consulting Fee | $15,127 | 11 | 9.7% |
| Food and Beverage | $6,215 | 79 | 4.0% |
| Honoraria | $6,103 | 3 | 3.9% |
| Education | $169.86 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $36,828 | 49 | $0 (2024) |
| Astellas Pharma US Inc | $22,957 | 25 | $0 (2024) |
| PFIZER INC. | $16,660 | 19 | $0 (2024) |
| Exelixis Inc. | $16,223 | 33 | $0 (2024) |
| Seagen Inc. | $14,960 | 18 | $0 (2023) |
| Merck Sharp & Dohme LLC | $14,553 | 15 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $13,191 | 16 | $0 (2024) |
| EMD Serono, Inc. | $8,957 | 8 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $4,239 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,848 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,629 | 111 | Janssen Biotech, Inc. ($24,395) |
| 2023 | $62,190 | 90 | Seagen Inc. ($13,399) |
| 2022 | $5,162 | 11 | Seagen Inc. ($1,562) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,190.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $791.70 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $144.23 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Hematology | ||||||
| 11/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $185.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,780.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $682.50 | General |
| 11/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $401.87 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $93.27 | General |
| Category: Oncology | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $553.39 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $46.80 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $46.80 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $46.80 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/09/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $46.80 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/08/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $276.48 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/08/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $145.83 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $425.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 10/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,138.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Oncology | ||||||
| 10/26/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 73 | 2,689 | 98,260 | $5.3M | $1.1M |
| 2022 | 12 | 208 | 490 | $73,524 | $15,176 |
Total Patients
2,897
Total Services
98,750
Medicare Billing
$1.1M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 33 | 17,200 | $2.4M | $745,037 | 31.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 18,180 | $363,600 | $42,733 | 11.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 137 | 370 | $261,590 | $39,822 | 15.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 1,980 | $131,520 | $36,595 | 27.8% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 37 | 103 | $284,486 | $30,999 | 10.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 15 | 276 | $372,048 | $22,627 | 6.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 139 | $68,944 | $19,400 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 176 | $64,768 | $17,585 | 27.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 76 | 87 | $92,829 | $16,006 | 17.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 110 | $27,500 | $7,877 | 28.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 51 | 131 | $45,064 | $6,896 | 15.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 91 | 132 | $41,316 | $6,793 | 16.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 59 | 64 | $30,080 | $6,435 | 21.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 91 | $19,201 | $5,466 | 28.5% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 13 | 27 | $18,900 | $5,321 | 28.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 107 | 417 | $45,036 | $5,270 | 11.7% |
| G6012 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | Office | 2023 | 11 | 26 | $18,200 | $5,109 | 28.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $19,852 | $4,731 | 23.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 87 | 398 | $25,472 | $4,119 | 16.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 62 | 178 | $28,658 | $4,105 | 14.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 30 | 66 | $16,302 | $4,042 | 24.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 40 | 108 | $14,580 | $4,002 | 27.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 71 | 83 | $68,143 | $3,972 | 5.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 13 | 2,730 | $21,840 | $3,752 | 17.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 71 | 140 | $21,980 | $3,319 | 15.1% |
About Michael Lattanzi
Michael Lattanzi is a Medical Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2016. The National Provider Identifier (NPI) number assigned to this provider is 1902255276.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Lattanzi has received a total of $155,982 in payments from pharmaceutical and medical device companies, with $88,629 received in 2024. These payments were reported across 212 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($92,638).
As a Medicare-enrolled provider, Lattanzi has provided services to 2,897 Medicare beneficiaries, totaling 98,750 services with total Medicare billing of $1.1M. Data is available for 2 years (2022–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Student in an Organized Health Care Education/Training Program, Hematology & Oncology
- Location Austin, TX
- Active Since 06/08/2016
- Last Updated 09/13/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1902255276
Products in Payments
- PADCEV (Biological) $25,145
- Padcev (Drug) $24,612
- ERLEADA (Drug) $22,342
- CABOMETYX (Drug) $16,223
- FOTIVDA (Drug) $13,056
- RYBREVANT (Drug) $9,176
- BAVENCIO (Drug) $8,702
- LYNPARZA (Biological) $5,408
- TALZENNA (Drug) $4,819
- KEYTRUDA (Biological) $4,166
- LYNPARZA (Drug) $3,814
- FYARRO (Drug) $1,500
- BALVERSA (Drug) $285.64
- DARZALEX (Biological) $257.46
- Nubeqa (Drug) $126.64
- Trodelvy (Drug) $114.78
- REBLOZYL (Biological) $31.45
- RETEVMO (Drug) $28.93
- ELIQUIS (Drug) $27.80
- FOUNDATIONONE CDX (Device) $26.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Austin
Dr. Jason Melear, M.d, M.D
Medical Oncology — Payments: $534,206
Medical Oncology $534,206
Sue Eckhardt, Md, MD
Medical Oncology — Payments: $419,765
Medical Oncology $419,765
Miguel Albino, Md, MD
Medical Oncology — Payments: $308,516
Medical Oncology $308,516
Dr. Aravind Ramakrishnan, M.d, M.D
Medical Oncology — Payments: $110,197
Medical Oncology $110,197
Dr. Laurence Tokaz, M.d, M.D
Medical Oncology — Payments: $46,331
Medical Oncology $46,331
Dr. John Sandbach, Md, MD
Medical Oncology — Payments: $7,649
Medical Oncology $7,649